Low blood pressure aids dialysis patients
Posted on: Wednesday, 25 February 2009, 23:21 CST
Lowering blood pressure protects dialysis patients from major cardiovascular events and death, researchers in Australia said.
The study, published in The Lancet, also said that treatment with blood-pressure lowering drugs should be routinely considered for patients undergoing dialysis.
Vlado Perkovic of The George Institute for International Health in Australia said people who receive dialysis for chronic kidney disease are at high risk of cardiovascular events and death -- every year about 10 percent and 20 percent of patients on dialysis die, with nearly half these deaths due to cardiovascular causes.
Perkovic and international colleagues systematically reviewed eight randomized controlled trials that assessed the effect of blood-pressure lowering in 1,679 adult patients on dialysis, and involved 495 cardiovascular events.
Overall, findings showed that treatment with blood-pressure lowering drugs was associated with a reduced risk of cardiovascular complications, all-cause mortality and cardiovascular deaths compared with controls.
Source: United Press International
Related Articles
- 1 In 20 Patients Experience Critical Event During Urgent Air-Medical Transport
- Compirion Healthcare Sponsors Webinar on 7 Mistakes That Lower Patient Satisfaction Scores
- Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients With Diabetes
- Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients With Diabetes
- ACTOS(R) (Pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
- Survey: Patients Taking Blood Thinners Need Extra Help From Their Providers
- European Commission Approves Kepivance(TM) (Palifermin) for Oral Mucositis in Cancer Patients Undergoing Blood and Bone Marrow Transplant
- Cardiovascular Care of Patients With Marfan Syndrome
- Landmark Trial Will Evaluate the Impact of Treating Anemia on Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Amgen Launches Landmark Trial to Evaluate the Impact of Treating Anemia on Cardiovascular Risks in Patients With Chronic Kidney Disease and Type 2 Diabetes
User Comments (0)

RSS Feeds